WO2026013622 - IRF4 DEGRADERS AND THEIR USE FOR TREATING CANCER AND AUTOIMMUNE DISEASE
National phase entry is expected:
Publication Number
WO/2026/013622
Publication Date
15.01.2026
International Application No.
PCT/IB2025/057017
International Filing Date
10.07.2025
Title **
[English]
IRF4 DEGRADERS AND THEIR USE FOR TREATING CANCER AND AUTOIMMUNE DISEASE
[French]
AGENTS DE DÉGRADATION DE L'IRF4 ET LEUR UTILISATION POUR LE TRAITEMENT DU CANCER ET D'UNE MALADIE AUTO-IMMUNE
Applicants **
DANA-FARBER CANCER INSTITUTE, INC.
Inventors
AGIUS, Michael
QI, Jun
LIU, Qi
GHOBRIAL, Irene
Priority Data
63/670,545
12.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2680 | |
| EPO | Filing, Examination, Granting | 14971 | |
| Japan | Filing, Examination, Granting | 2493 | |
| South Korea | Filing, Examination, Granting | 2756 | |
| USA | Filing, Examination, Granting | 6540 |
Total:
29,440
Contact Us
Abstract[English]
The invention relates to compounds useful for degradation of interferon regulatory factor 4 (IRF4), pharmaceutical compositions comprising such compounds and methods for treating diseases related to IRF4 activity, such as cancer, using such compounds.[French]
L'invention concerne des composés utiles pour la dégradation du facteur de régulation de l'interféron 4 (IRF4), des compositions pharmaceutiques comprenant de tels composés et des méthodes de traitement de maladies liées à l'activité de l'IRF4, telles que le cancer, à l'aide de tels composés.